Skip to main content
Lupin Ltd logo

Lupin Ltd — Investor Relations & Filings

Ticker · LUPIN ISIN · INE326A01037 LEI · 335800HHXTESDEE2FC65 BSE.NS Manufacturing
Open in API
Filings indexed 3,174 across all filing types
Latest filing 2024-06-07 Regulatory Filings
Country IN India
Listing BSE.NS LUPIN

About Lupin Ltd

https://www.lupin.com/

Lupin Ltd is a global pharmaceutical organization specializing in the development, manufacturing, and marketing of a comprehensive range of generic and branded formulations, biotechnology products, and active pharmaceutical ingredients. The company holds a significant market position in therapeutic segments such as cardiovascular, diabetology, asthma, pediatrics, gastrointestinal, anti-infectives, and non-steroidal anti-inflammatory drugs. It is notably recognized for its leadership in the anti-tuberculosis medication sector. With a strong emphasis on research and development, Lupin focuses on complex generics, specialty medicines, and biosimilars. The company operates advanced manufacturing facilities and maintains a substantial commercial presence across major global markets, including North America, Europe, and the Asia-Pacific region, delivering affordable and high-quality healthcare solutions.

Recent filings

Filing Released Lang Actions
Lupin Limited entered into a Business Transfer Agreement with Lupin Life Sciences Limited, its wholly owned subsidiary in connection with the carve out of its trade generics business in ....
Regulatory Filings Classification · 95% confidence The document is a letter addressed to stock exchanges disclosing a business transfer agreement (BTA) entered into by Lupin Limited with its wholly owned subsidiary. It references Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which pertains to disclosure of material events. The document is short (2001 characters) and serves as an announcement of a corporate transaction rather than a detailed report or financial statement. It does not contain financial data or detailed analysis but is a regulatory disclosure about a business transfer event. This fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2024-06-07 English
Updates
Regulatory Filings Classification · 95% confidence The document is a short disclosure letter addressed to stock exchanges regarding a Business Transfer Agreement (BTA) entered into by Lupin Limited with its wholly owned subsidiary. It references Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which pertains to disclosure of material events. The document is only 2003 characters long and serves as an announcement of a corporate transaction (business carve-out on a slump sale basis) rather than a detailed report or financial statement. It does not contain financial data, management discussion, or detailed analysis. It is a regulatory disclosure announcement about a corporate event, fitting best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories like M&A filings or capital updates. Therefore, the appropriate classification is Regulatory Filings (RNS).
2024-06-07 English
Updates on acquisition of a portfolio of accretive established products in Europe and Canada.
Capital/Financing Update Classification · 95% confidence The document is a disclosure pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which relates to updates on acquisition activity. It announces the completion of an acquisition of product brands by a subsidiary of Lupin Limited. The text explicitly states this is a disclosure under Listing Regulations and does not contain detailed financial statements or analysis. It is an announcement of a capital transaction (acquisition) rather than a full report or detailed financing update. Therefore, it fits best under Capital/Financing Update (CAP). The document length is short and it is not a report publication announcement or certification. Hence, the classification is CAP with high confidence.
2024-06-05 English
Acquisition
Capital/Financing Update Classification · 95% confidence The document is a disclosure pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which relates to updates on an acquisition transaction. It announces the completion of the acquisition of a portfolio of product brands by a subsidiary of Lupin Limited. The document is relatively short (2056 characters) and serves as an announcement of a corporate event rather than a detailed financial report or presentation. It does not contain financial statements or detailed analysis but is a regulatory disclosure about a transaction completion. This fits the category of Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes, including acquisitions of assets or brands.
2024-06-05 English
Press Release
M&A Activity Classification · 95% confidence The document is a press release announcing the completion of an acquisition by Lupin Limited's subsidiary of two brands from Sanofi. It is addressed to stock exchanges and references compliance with SEBI Listing Regulations. The content focuses on the acquisition details, strategic rationale, and company background. There are no financial statements, detailed financial performance data, or regulatory filings such as annual or quarterly reports. The document is a corporate announcement about a transaction, specifically an acquisition, rather than a full merger filing or tender offer document. Therefore, it fits best under the category of M&A Activity (TAR), which covers announcements and documents related to merger proposals or takeover bids, including acquisitions.
2024-06-05 English
Lupin completes Acquisition of two Brands from Sanofi in Europe and Canada.
Capital/Financing Update Classification · 95% confidence The document is a press release announcing the completion of an acquisition by Lupin Limited's subsidiary of two brands from Sanofi. It is addressed to stock exchanges and references compliance with SEBI Listing Regulations, specifically Regulation 30, which pertains to disclosure of material events. The content focuses on the acquisition transaction details, strategic rationale, and company background. There are no financial statements, detailed financial analysis, or comprehensive report data included. The document is a formal announcement of a corporate transaction rather than a full report or detailed financial filing. Therefore, it fits best under the category of Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes such as acquisitions.
2024-06-05 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.